At a glance
- Originator Schering-Plough
- Developer OPKO Health
- Class Antiemetics
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cough; Major depressive disorder; Overactive bladder
- Discontinued Chemotherapy-induced nausea and vomiting
Most Recent Events
- 22 Jan 2019 TESARO has been acquired and merged into GlaxoSmithKline
- 17 Jun 2015 No recent reports on development identified - Phase-I for Cough, Major depressive disorder and Overactive bladder in USA (PO)